Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Supernus Pharmaceuticals (SUPN) and Indivior completed their merger, creating Supernus, Inc. The combined company will trade on Nasdaq under 'SUPN' starting November 3, 2026. The merger enhances financial flexibility, expands the CNS-focused portfolio, and positions the company for long-term growth. Former Indivior shareholders will receive a $1 billion cash dividend, financed by debt and existing cash.
How this was made
The 30-second read
Why it matters
The deal adds scale, cash flow, and a broader product suite, likely driving positive investor sentiment and short-term price moves.
Market read
First report of a major CNS biotech merger with a new Nasdaq ticker, offering immediate trading opportunities.
What to watch
Potential antitrust review and execution risk of merging product pipelines.
Background
Supernus Pharmaceuticals and Indivior Pharmaceuticals completed a merger, forming a diversified CNS biopharma with a new ticker SUPN.
Ticker impact
Completion of merger creates new Nasdaq-listed company SUPN, trading starts Nov 3 2026.
likely upside as investors price in synergies and new ticker debut
First report of merger completion, new ticker, and $1B cash dividend signal strong financial flexibility.
Indivior shareholders receive cash dividend and will be delisted after merger; its former shareholders own ~56.5% of SUPN.
downward pressure as INDV is delisted and converted to SUPN shares
Merger completion mandates conversion; market will adjust INDV price to reflect conversion ratio.
Market effects
Consolidation in CNS biotech may boost sector confidence and spur M&A activity.
Strengthens US biotech market with larger, diversified player.
Creates a globally competitive CNS drug developer, affecting worldwide treatment markets.
Counterpoint
Integration challenges and regulatory hurdles could dampen expected synergies.
Key entities
- companySupernus Pharmaceuticals
US-listed CNS biopharma merging into SUPN.
- companyIndivior Pharmaceuticals
US-listed opioid treatment company merging into SUPN.
